Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05317390 · ClinicalTrials.gov registry record · NA
Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia
A NA study of Parkinson Disease and Essential Tremor, sponsored by Massachusetts Eye and Ear Infirmary.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT05317390: Recruiting NA study of Parkinson Disease and Essential Tremor, sponsored by Massachusetts Eye and Ear Infirmary.
NCT05317390 is a NA study of Parkinson Disease and Essential Tremor that is actively recruiting participants, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 1,000 participants, below the 5,323-participant average among 297 other Parkinson Disease trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05317390, a NA study of Parkinson Disease and Essential Tremor, is actively recruiting participants, sponsored by Massachusetts Eye and Ear Infirmary.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This research involves retrospective and prospective studies for clinical validation of a DystoniaNet deep learning platform for the diagnosis of isolated dystonia.
Primary Outcome
Correctness of dystonia diagnosis (yes dystonia/no dystonia) will be established using the DystoniaNet machine-learning algorithm
Conditions Studied
Interventions
- DIAGNOSTIC_TEST DystoniaNet-based diagnosis of isolated dystonia
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2028-04-30 |
| Phase | NA |
What NCT05317390 shows while recruiting
NCT05317390 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 5,323-participant average among 297 other Parkinson Disease trials with a reported enrollment target (81% lower).
The record links to 10 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which DystoniaNet-based diagnosis of isolated dystonia is the first listed.
NCT05317390 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05317390 about?
NCT05317390 is a clinical study titled "Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia". This research involves retrospective and prospective studies for clinical validation of a DystoniaNet deep learning platform for the diagnosis of isolated dystonia.
What is the current status of trial NCT05317390?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2022-06-01. Estimated completion is 2028-04-30.
What conditions does trial NCT05317390 study?
This clinical trial studies the following conditions: Parkinson Disease, Essential Tremor, Dystonia, Tic Disorders, Dyskinesias.
What interventions are being tested in trial NCT05317390?
The interventions under investigation include: DystoniaNet-based diagnosis of isolated dystonia (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05317390?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05317390 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05317390's enrollment target sits among peer trials
1,000 12th of 297 higher than 282 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Neurophysiology of Reward Signaling in Parkinson's Disease
RECRUITING · NA
-
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
RECRUITING · NA
-
Rock Steady Boxing: A Community Based In Person Class
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI